BRECKENRIDGE
GenericsBRECKENRIDGE is a generic drug manufacturer focused on Neurology, Cardiovascular, Immunology.
BRECKENRIDGE's Key Drugs
BRECKENRIDGE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BRECKENRIDGE's Recent FDA Approvals
BRECKENRIDGE secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
BRECKENRIDGE's Therapeutic Areas
BRECKENRIDGE's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BRECKENRIDGE's Top Competitors
BRECKENRIDGE's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BRECKENRIDGE Pipeline Snapshot
Active clinical trials for BRECKENRIDGE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2006-05-26
- Latest
- 2026-09-21
- Applications
- 45